Reportable Segments and Major Customers Information (Tables)

9 Months Ended

Jun. 30, 2018

Segment information for the interim periods is as follows:


	Diagnostics		Life Science		Unallocated Costs and Eliminations(1)			Total
Three Months Ended June 30, 2018
Net revenues -
Third-party	$	36,368	$	15,369	$	—		$	51,737
Inter-segment		80		96		(176	)		—
Operating income		7,166		3,647		(2,078	)		8,735
Goodwill (June 30, 2018)		35,213		19,563		—			54,776
Other intangible assets, net (June 30, 2018)		22,749		1,226		—			23,975
Total assets (June 30, 2018)		183,233		71,375		(625	)		253,983
Three Months Ended June 30, 2017
Net revenues -
Third-party	$	35,949	$	14,191	$	—		$	50,140
Inter-segment		71		129		(200	)		—
Operating income (2)		914		3,388		2			4,304
Goodwill (September 30, 2017)		35,213		19,713		—			54,926
Other intangible assets, net (September 30, 2017)		24,973		1,731		—			26,704
Total assets (September 30, 2017)		180,226		69,938		(387	)		249,777
Nine Months Ended June 30, 2018
Net revenues -
Third-party	$	113,640	$	46,831	$	—		$	160,471
Inter-segment		281		363		(644	)		—
Operating income		22,926		10,007		(8,459	)		24,474
Nine Months Ended June 30, 2017
Net revenues -
Third-party	$	107,529	$	43,545	$	—		$	151,074
Inter-segment		278		361		(639	)		—
Operating income (2)		17,152		11,226		197			28,575

(1)

Unallocated costs for the three and nine months ended June 30, 2018 total $2,081 and $8,475, respectively, and are comprised of Executive Transition and Realignment Costs, and Litigation Costs, as set forth within the accompanying Condensed Consolidated Statements of Operations. Eliminations consist of inter-segment transactions.

(2)	Diagnostics’ operating income includes the effect of the Magellan goodwill impairment charge in the amount of $6,628 during the three and nine month periods ended June 30, 2017.